Join Date
October 2024
Country
Gender
Not Specified
Age
Not Specified
About Michael Chu
Michael graduated, PhD, from the Department of Biomedical Engineering at the University of California Irvine, where he worked in Dr. Michelle Khine’s lab. His research focused on developing and using soft wearable sensors for noninvasive monitoring of physiologic vital signs. Michael has helped author over 10 peer reviewed papers and is also inventor of 3 patents submitted by the lab. His dissertation work served as the foundation for the Makani Science technology.
Companies & Work
Makani Science
Makani Science is a medical device company based in Irvine, California. We have created the world's first wireless patch that can accurately and continuously monitor breathing. The company is co-founded by Dr. Michelle Khine and Dr. Michael Chu, two experts in the wearable monitoring space from the University of California, Irvine.
The Makani Science system will collect unique breathing waveforms from patients in everyday environments to create the first large database of respiratory patterns associated with different diseases. Data will be collected through systems sold to our initial beachhead market, where we will help improve monitoring safety in patients being sedated for medical procedures. Our long-term goal is to combine machine learning with this database to identify and predict respiratory complications for different patient populations.
We have a highly experienced team and will be FDA cleared in our beachhead market within a year.
The Makani Science system will collect unique breathing waveforms from patients in everyday environments to create the first large database of respiratory patterns associated with different diseases. Data will be collected through systems sold to our initial beachhead market, where we will help improve monitoring safety in patients being sedated for medical procedures. Our long-term goal is to combine machine learning with this database to identify and predict respiratory complications for different patient populations.
We have a highly experienced team and will be FDA cleared in our beachhead market within a year.
